News


  • 31 July 2014

    Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models

    Entinostat Improves Treatment Outcomes When Combined with Immune Checkpoint Blockade in Preclinical Tumor Models

    Syndax Pharmaceuticals, Inc. today announced that newly published results demonstrate that in preclinical studies entinostat significantly improved treatment outcomes in mouse tumor models when combined with anti-PD1 and anti-CTLA4 targeted antibodies. The paper from Kim, et al. at The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, titled "Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid derived cells" was published in the journal Proceedings of the National Academy of Sciences (PNAS). 

  • 30 July 2014

    Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

    Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

    Epic Sciences, Inc. ("Epic"), a privately held biotech company that designs and develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today the completion of a $30 million Series C Preferred Stock financing. The financing included new investors RusnanoMedInvest (RMI) and Arcus Ventures, existing investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as undisclosed individual investors. With the proceeds of the financing, Epic will commercialize its circulating rare cell analysis platform with special focus on developing products and services to detect circulating tumor cells (CTC) in cancer. Epic's technology enables the rapid and minimally invasive characterization of protein biomarker and genomic profiles in CTCs allowing for superior therapy selection and the early drug resistance detection.

  • 30 June 2014

    First Patient Enrolled in ECOG-ACRIN Phase III Trial of Syndaxs Entinostat

    First Patient Enrolled in ECOG-ACRIN Phase III Trial of Syndaxs Entinostat

    The ECOG-ACRIN Cancer Research Group and Syndax Pharmaceuticals Inc. announced today enrollment of the first patient in E2112, a randomized phase III clinical trial of Syndax’s histone deacetylase (HDAC) inhibitor, entinostat, for the treatment of patients with advanced breast cancer. The trial is evaluating whether the addition of entinostat to endocrine therapy (exemestane, a steroidal aromatase inhibitor) improves progression-free survival and/or overall survival in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative advanced breast cancer who have progressed following treatment with a non-steroidal aromatase inhibitor.

  • 18 June 2014

    Vladimir Gurdus to speak about latest developments of RusnanoMedInvest and NovaMedica projects at 20th Pharmaceutical Forum in St. Petersburg

    Vladimir Gurdus to speak about latest developments of RusnanoMedInvest and NovaMedica projects at 20th Pharmaceutical Forum in St. Petersburg

    “We have worked our way up from the concept of RusnanoMedInvest portfolio building to first sales of NovaMedica pharmaceutical company within two years’ time. This pace of development is considered fast in the pharmaceutical industry”, - Vladimir Gurdus, CEO, RMI Partners, Management Company of RusnanoMedInvest (RMI) and NovaMedica said during his speech at 20th Russian Pharmaceutical Forum in St. Petersburg.

  • 10 June 2014

    NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio with Three New Antigens via Series of Rights Acquisitions

    NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio with Three New Antigens via Series of Rights Acquisitions

    NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has acquired the rights, in four separate transactions, to three well-studied Candida vaccine antigens, significantly bolstering the Company’s Candida vaccine pipeline. 

  • 28 May 2014

    Tragaras TG02 is Highly Active in CLL Cells Derived from Patients

    Tragaras TG02 is Highly Active in CLL Cells Derived from Patients

    TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy.

  • 22 May 2014

    NovaMedica is recognized one of the best employers of Russia in 2013

    NovaMedica is recognized one of the best employers of Russia in 2013

    Russian pharmaceutical company “NovaMedica” won “Best Employer” prize as part of the National business award “Captains of the Russian Business”. The award winners are selected by the professional jury following the results of market experts’ opinion and companies’ activities survey over the past year.

  • 14 May 2014

    Regado Biosciences Announces First Quarter 2014 Financial Results and Corporate Highlights

    Regado Biosciences Announces First Quarter 2014 Financial Results and Corporate Highlights

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of the Revolixys™ Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced its first quarter 2014 corporate highlights and financial results. A conference call and webcast to discuss the results will be held, May 14, 2014, at 8:30 a.m. EDT.

  • 03 April 2014

    Evgeny Zaytsev, Managing Partner, RMI Partners: "It is great to witness young scientists grasping significant medical problems and addressing important global science trends"

    Evgeny Zaytsev, Managing Partner, RMI Partners: "It is great to witness young scientists grasping significant medical problems and addressing important global science trends"

    Two Russian biopharmaceutical projects teams, specializing in innovative medical technology developments, were awarded special prizes of RUSNANO development institutes as part of the Forum U-NOVUS and the contest of young scientists developments hosted in Tomsk.

     

  • 02 April 2014

    Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1

    Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care cardiovascular indications, today announced that after achieving the 1,000-patient enrollment milestone, enrollment in the REGULATE-PCI trial has been extended to non ST-elevated myocardial infarction (N-STEMI) patients to include the planned “all comers” percutaneous coronary intervention (PCI) patient population described in the trial protocol.